Literature DB >> 9351514

Anti-inflammatory activity of cationic lipids.

M C Filion1, N C Phillips.   

Abstract

1. The effect of liposome phospholipid composition has been assumed to be relatively unimportant because of the presumed inert nature of phospholipids. 2. We have previously shown that cationic liposome formulations used for gene therapy inhibit, through their cationic component, the synthesis by activated macrophages of the pro-inflammatory mediators nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha). 3. In this study, we have evaluated the ability of different cationic lipids to reduce footpad inflammation induced by carrageenan and by sheep red blood cell challenge. 4. Parenteral (i.p. or s.c) or local injection of the positively charged lipids dimethyldioctadecylammomium bromide (DDAB), dioleyoltrimethylammonium propane (DOTAP), dimyristoyltrimethylammonium propane (DMTAP) or dimethylaminoethanecarbamoyl cholesterol (DC-Chol) significantly reduced the inflammation observed in both models in a dose-dependent manner (maximum inhibition: 70-95%). 5. Cationic lipids associated with dioleyol- or dipalmitoyl-phosphatidylethanolamine retained their anti-inflammatory activity while cationic lipids associated with dipalmitoylphosphatidylcholine (DPPC) or dimyristoylphosphatidylglycerol (DMPG) showed no anti-inflammatory activity, indicating that the release of cationic lipids into the macrophage cytoplasm is a necessary step for anti-inflammatory activity. The anti-inflammatory activity of cationic lipids was abrogated by the addition of dipalmitoylphosphatidylethanolamine-poly(ethylene)glycol-2000 (DPPE-PEG2000) which blocks the interaction of cationic lipids with macrophages. 6. Because of the significant role of protein kinase C (PKC) in the inflammatory process we have determined whether the cationic lipids used in this study inhibit PKC activity. The cationic lipids significantly inhibited the activity of PKC but not the activity of a non-related protein kinase, PKA. The synthesis of interleukin-6 (IL-6), which is not dependent on PKC activity for its induction in macrophages, was not modified in vitro or in situ by cationic lipids. The synthesis of NO and TNF-alpha in macrophages, both of which are PKC-dependent, was downregulated by cationic lipids. 7. These results demonstrate that cationic lipids can be considered as novel anti-inflammatory agents. The downregulation of pro-inflammatory mediators through interaction of cationic lipids with the PKC pathway may explain this anti-inflammatory activity. Furthermore, since cationic lipids have intrinsic anti-inflammatory activity, cationic liposomes should be used with caution to deliver nucleic acids for gene therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351514      PMCID: PMC1564955          DOI: 10.1038/sj.bjp.0701396

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

2.  Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats.

Authors:  Susanne Herber-Jonat; Rashmi Mittal; Stefan Gsinn; Hermann Bohnenkamp; Eric Guenzi; Andreas Schulze
Journal:  Inflamm Res       Date:  2010-10-12       Impact factor: 4.575

3.  Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.

Authors:  Ashish V Kalra; Robert B Campbell
Journal:  Pharm Res       Date:  2006-10-26       Impact factor: 4.580

Review 4.  Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

Authors:  Philippe Daull; Frédéric Lallemand; Jean-Sébastien Garrigue
Journal:  J Pharm Pharmacol       Date:  2014-04       Impact factor: 3.765

Review 5.  Relevance of Lipid-Based Products in the Management of Dry Eye Disease.

Authors:  Jean-Sébastien Garrigue; Mourad Amrane; Marie-Odile Faure; Juha M Holopainen; Louis Tong
Journal:  J Ocul Pharmacol Ther       Date:  2017-09-28       Impact factor: 2.671

6.  Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial.

Authors:  Paolo Fogagnolo; Chiara Quisisana; Anna Caretti; Daniele Marchina; Michele Dei Cas; Ettore Melardi; Luca Rossetti
Journal:  Clin Ophthalmol       Date:  2020-06-18

7.  Anti-arthritis activity of cationic materials.

Authors:  Lei Dong; Suhua Xia; Huan Chen; Jiangning Chen; Junfeng Zhang
Journal:  J Cell Mol Med       Date:  2009-06-16       Impact factor: 5.310

8.  Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.

Authors:  Wei He; Pei Liang; Guangxing Guo; Zhen Huang; Yiming Niu; Lei Dong; Chunming Wang; Junfeng Zhang
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

9.  Anti-inflammatory activity of CKC-containing cationic emulsion eye drop vehicles.

Authors:  Philippe Daull; Samuel Guenin; Valérie Hamon de Almeida; Jean-Sébastien Garrigue
Journal:  Mol Vis       Date:  2018-07-20       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.